O’FALLON, Mo.--(BUSINESS WIRE)--Synergetics USA, Inc. (NASDAQ: SURG) (“Synergetics” or the “Company”) today announced its preliminary results for the third fiscal quarter ended April 30, 2010 related to the allocation of proceeds from the settlement, license and supply agreement with Alcon Laboratories, Inc. and the expected gain from the sale of the Omni® product line to Stryker Corporation. The Company stated during an investor conference call on April 28, 2010 that it would pre-announce the impact of these transactions as soon as the results were available:
